State health insurance bureau: in the first half of 2019, the accumulated reimbursement amount of 17 anticancer drugs exceeded 1.9 billion yuan

From January to June 2019, a total of 318200 people and 1.963 billion yuan were reimbursed for anticancer drugs negotiated by 17 kinds of national medical insurance, the State Medical Insurance Bureau said Thursday The state health insurance bureau will continue to promote the national health insurance negotiation on the allocation and use of anticancer drugs in medical institutions, and safeguard the rights and interests of cancer patients In October 2018, the state health insurance bureau issued a notice to include 17 kinds of negotiated anti-cancer drugs into the category B scope of the national basic medical insurance, work injury insurance and maternity insurance drugs catalogue Among the 17 kinds of drugs, including 12 solid tumor drugs and 5 blood tumor drugs, they are all clinically necessary, effective and urgently needed by the insured Compared with the average retail price, the payment standard of negotiated drugs decreased by 56.7% on average The National Health Insurance Bureau stressed that the health departments in all regions should further improve the tumor diagnosis and treatment standards and guidelines for the clinical application of anti-tumor drugs, guide medical institutions to equip necessary drugs and optimize the drug structure according to the tumor diagnosis and treatment standards and capabilities The hospital shall not influence the supply guarantee and rational drug demand of negotiated drugs on the grounds of total cost control, total medical insurance cost control and drug proportion According to reports, the National Health Insurance Bureau has recently launched a new round of health insurance catalog adjustment The catalog adjustment will be based on the principle of "making up the short board guarantee", giving priority to the national basic drugs, cancer and rare diseases and other major disease treatment drugs, chronic disease drugs and other categories The state health insurance bureau said it will establish a dynamic adjustment mechanism for the medical insurance catalogue, strive to achieve the goal of more optimized drug structure, more standardized management and higher efficiency in the use of medical insurance funds, so as to further improve the level of drug security, including anti-cancer drugs At the same time, we will continue to promote the allocation and use of anticancer drugs in medical institutions under the national health insurance negotiation, further standardize the selection, purchase and use of anticancer drugs by medical institutions, and safeguard the rights and interests of cancer patients.